FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

NCT04245722 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

98

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by the Sponsor.

Conditions

Lymphoma, B-Cell
Chronic Lymphocytic Leukemia

Interventions

DRUG: FT596
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Rituximab
DRUG: Obinutuzumab
DRUG: Bendamustine

Sponsor

Fate Therapeutics